Evidence map›Paper›PMID 34099515›Full record

ArticleDiabetes care2021

Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients With Diabetes.

Georgia M Davis, Elias K Spanakis, Alexandra L Migdal, Lakshmi G Singh, Bonnie Albury, Maria Agustina Urrutia, K Walkiria Zamudio-Coronado, William H Scott, Rebecca Doerfler, Sergio Lizama and 8 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03508934 naactive not recruitingnot on this map

Continuous Glucose Monitoring in Insulin Treated Hospitalized Veterans With DM2 at Higher Risk for Hypoglycemia

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2018 to 2026Enrolled218ConditionsDiabetes Mellitus, Type 2, HypoglycemiaArmsGTS (Continuous Glucose Monitoring), POC (Point of Care)
NCT05135676 nacompletednot on this mapstarted 2022, after this paper: background citation

Time in Glucose Hospital Target (TIGHT) - A Randomized Clinical Trial to Evaluate the Use of CGM to Achieve a Mean Glucose Target of 90 to 130 mg/dL Without Hypoglycemia in Hospitalized Adults With Type 2 Diabetes

TypeinterventionalSponsorJaeb Center for Health ResearchRan2022 to 2024Enrolled169ConditionsDiabetes Mellitus, Type 2ArmsBlinded CGM, real-time CGM
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Observational
  14. Inpatient Diet Orders and Continuous Glucose Monitoring in Noncritically Ill, Hospitalized Adult Patients.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Observational
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Georgia M DavisDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Elias K SpanakisDivision of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD.ORCID 0000-0002-9352-7172
Alexandra L MigdalDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Lakshmi G SinghDivision of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD.
Bonnie AlburyDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Maria Agustina UrrutiaDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
K Walkiria Zamudio-CoronadoDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
William H ScottDivision of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore, MD.
Rebecca DoerflerDivision of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD.
Sergio LizamaDivision of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD.
Medha SatyarenggaDivision of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD.
Kashif MunirDivision of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD.
Rodolfo J GalindoDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0002-9295-3225
Priyathama VellankiDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Saumeth CardonaDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.
Francisco J PasquelDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA.ORCID 0000-0002-3845-6703
Limin PengDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA.
Guillermo E UmpierrezDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA geumpie@emory.edu.ORCID 0000-0002-3252-5026
Emory University · USUniversity of Maryland, Baltimore · USVeterans Health Administration · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery PatientsK23GM128221 · NIGMS · EMORY UNIVERSITY · PI PASQUEL, FRANCISCO J · 2018 to 2022
$957k
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 DiabetesK23DK123384 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GALINDO, RODOLFO · 2020 to 2024
$934k
Perioperative Stress Hyperglycemia in General and Vascular Surgery PatientsK23DK122199 · NIDDK · EMORY UNIVERSITY · PI DAVIS, GEORGIA M · 2020 to 2024
$891k
Epigenetic Markers of Short- and Long- Term Near-Normoglycemia Remission in Patients with Ketosis-Prone DiabetesK23DK113241 · NIDDK · EMORY UNIVERSITY · PI VELLANKI, PRIYATHAMA · 2019 to 2021
$646k
Continuous Glucose Monitoring in Insulin Treated Hospitalized Veterans with DM2 at Higher Risk for HypoglycemiaI01CX001825 · VA · BALTIMORE VA MEDICAL CENTER · PI SPANAKIS, ILIAS · 2018 to 2023
–
CSRD VA I01 CX001825NCATS NIH HHS UL1 TR002378NIDDK NIH HHS K23 DK113241NIDDK NIH HHS K23 DK122199NIDDK NIH HHS K23 DK123384NIDDK NIH HHS P30 DK111024NIGMS NIH HHS K23 GM128221
6 · The paper itself

Abstract

objectiveAdvances in continuous glucose monitoring (CGM) have transformed ambulatory diabetes management. Until recently, inpatient use of CGM has remained investigational, with limited data on its accuracy in the hospital setting. RESEARCH DESIGN AND

methodsTo analyze the accuracy of Dexcom G6, we compared retrospective matched-pair CGM and capillary point-of-care (POC) glucose data from three inpatient CGM studies (two interventional and one observational) in general medicine and surgery patients with diabetes treated with insulin. Analysis of accuracy metrics included mean absolute relative difference (MARD), median absolute relative difference (ARD), and proportion of CGM values within 15, 20, and 30% or 15, 20, and 30 mg/dL of POC reference values for blood glucose >100 mg/dL or ≤100 mg/dL, respectively (% 15/15, % 20/20, % 30/30). Clinical reliability was assessed with Clarke error grid (CEG) analyses.

resultsA total of 218 patients were included (96% with type 2 diabetes) with a mean age of 60.6 ± 12 years. The overall MARD (

conclusionsOur results indicate that CGM technology is a reliable tool for hospital use and may help improve glucose monitoring in non-critically ill hospitalized patients with diabetes.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2AgedBlood GlucoseBlood Glucose Self-MonitoringHumansMiddle AgedReproducibility of ResultsRetrospective StudiesBlood Glucose

Identifiers

PMID34099515
PMCPMC8323182
OpenAlexW3168630898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.